- Home
- LANV vs CMPX Comparison
LANV vs CMPX Comparison
Compare LANV & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- CMPX
- Stock Information
- Founded
- LANV 2015
- CMPX 2014
- Country
- LANV China
- CMPX United States
- Employees
- LANV N/A
- CMPX N/A
- Industry
- LANV Blank Checks
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- LANV Finance
- CMPX Health Care
- Exchange
- LANV Nasdaq
- CMPX Nasdaq
- Market Cap
- LANV 173.2M
- CMPX 217.4M
- IPO Year
- LANV N/A
- CMPX N/A
- Fundamental
- Price
- LANV $1.73
- CMPX $1.58
- Analyst Decision
- LANV
- CMPX Strong Buy
- Analyst Count
- LANV 0
- CMPX 2
- Target Price
- LANV N/A
- CMPX $9.00
- AVG Volume (30 Days)
- LANV 84.8K
- CMPX 401.2K
- Earning Date
- LANV 08-26-2024
- CMPX 08-12-2024
- Dividend Yield
- LANV N/A
- CMPX N/A
- EPS Growth
- LANV N/A
- CMPX N/A
- EPS
- LANV N/A
- CMPX N/A
- Revenue
- LANV $409,961,427.00
- CMPX $850,000.00
- Revenue This Year
- LANV N/A
- CMPX N/A
- Revenue Next Year
- LANV $76.77
- CMPX $950.68
- P/E Ratio
- LANV N/A
- CMPX N/A
- Revenue Growth
- LANV N/A
- CMPX N/A
- 52 Week Low
- LANV $0.91
- CMPX $0.77
- 52 Week High
- LANV $4.70
- CMPX $2.34
- Technical
- Relative Strength Index (RSI)
- LANV 54.96
- CMPX 65.76
- Support Level
- LANV $1.65
- CMPX $1.42
- Resistance Level
- LANV $1.85
- CMPX $1.61
- Average True Range (ATR)
- LANV 0.19
- CMPX 0.12
- MACD
- LANV 0.01
- CMPX 0.02
- Stochastic Oscillator
- LANV 46.60
- CMPX 66.56
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.